In vitro diagnosis (IVD) is a diagnostic method of testing human samples such as blood, urine and other human samples in the human body. At present, about two -thirds of global medical decisions are based on diagnosis, and more than 80%of the diagnosis belongs to the in vitro diagnosis. In vitro diagnosis is a high -tech industry. The core of the industry lies in the technical platform and response system of diagnosis and testing. The core competitiveness of the enterprise is mainly its technical level. Divided by testing methods or principles, Chinese external diagnostic reagents include biochemical diagnosis, immune diagnosis, molecular diagnosis, POCT (instant diagnosis), coagulation diagnosis, and hematology. Ter molecular diagnosis, as the technical foundation of precision medical care, is the cutting -edge technology of diagnostic technology, and the fastest growing sub -industry in the IVD field. Molecular diagnosis mainly refers to the detection of various structural proteins, enzymes, antigen antibodies, and immune activity molecular genes related to disease -related diseases. It is one of the important frontier areas of contemporary medical development. Molecular diagnostic technology mainly includes polymerase chain reactions (PCR), fluorescent in situ, gene chips and gene sequencing technology. At present, PCR technology is still the mainstream of molecular diagnosis. In the long run, gene sequencing technology is more promising and represents future development direction. Her gene sequencing technology represented by NGS technology has been applied in a large scale in the field of non -invasive prenatal diagnosis (NIPT). The risk of the hyperthermia (such as Tang's syndrome). Compared with traditional methods such as amniotic stab and serum testing, NIPT has the advantages of sensitivity and safety. The largest application field of NGS technology in the future is the accompany diagnosis (CDX) and tumor early screening of precision drug use of tumors. In addition to the early "three -board ax", in addition to surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy have become a new choice. Patients with targeted treatment objects in principle must be strictly limited to patients with corresponding targets. For example, gifdin niginibinibininibicinic tablets must be used in patients with lung cancer who occur in EGFR drug allergies. Whether this patient is suitable for a certain targeted drug treatment is called accompanying diagnosis, also known as personalized drug testing. Through this test, clinicians can determine whether patients can benefit from specific treatment, or avoid serious risk of toxic and side effects. They can also evaluate the treatment effect and monitor the condition. sex. Personalized medication testing is an important part of precision medical care, which can not only diagnose the disease, but also help identify the patient's response to targeted drugs, and aims to help patients formulate correct treatment decisions.
In vitro diagnosis (IVD) is a diagnostic method of testing human samples such as blood, urine and other human samples in the human body. At present, about two -thirds of global medical decisions are based on diagnosis, and more than 80%of the diagnosis belongs to the in vitro diagnosis. In vitro diagnosis is a high -tech industry. The core of the industry lies in the technical platform and response system of diagnosis and testing. The core competitiveness of the enterprise is mainly its technical level. Divided by testing methods or principles, Chinese external diagnostic reagents include biochemical diagnosis, immune diagnosis, molecular diagnosis, POCT (instant diagnosis), coagulation diagnosis, and hematology.
Ter molecular diagnosis, as the technical foundation of precision medical care, is the cutting -edge technology of diagnostic technology, and the fastest growing sub -industry in the IVD field. Molecular diagnosis mainly refers to the detection of various structural proteins, enzymes, antigen antibodies, and immune activity molecular genes related to disease -related diseases. It is one of the important frontier areas of contemporary medical development. Molecular diagnostic technology mainly includes polymerase chain reactions (PCR), fluorescent in situ, gene chips and gene sequencing technology. At present, PCR technology is still the mainstream of molecular diagnosis. In the long run, gene sequencing technology is more promising and represents future development direction.
Her gene sequencing technology represented by NGS technology has been applied in a large scale in the field of non -invasive prenatal diagnosis (NIPT). The risk of the hyperthermia (such as Tang's syndrome). Compared with traditional methods such as amniotic stab and serum testing, NIPT has the advantages of sensitivity and safety.
The largest application field of NGS technology in the future is the accompany diagnosis (CDX) and tumor early screening of precision drug use of tumors. In addition to the early "three -board ax", in addition to surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy have become a new choice. Patients with targeted treatment objects in principle must be strictly limited to patients with corresponding targets. For example, gifdin niginibinibininibicinic tablets must be used in patients with lung cancer who occur in EGFR drug allergies. Whether this patient is suitable for a certain targeted drug treatment is called accompanying diagnosis, also known as personalized drug testing. Through this test, clinicians can determine whether patients can benefit from specific treatment, or avoid serious risk of toxic and side effects. They can also evaluate the treatment effect and monitor the condition. sex. Personalized medication testing is an important part of precision medical care, which can not only diagnose the disease, but also help identify the patient's response to targeted drugs, and aims to help patients formulate correct treatment decisions.